Pharmacotyping of Pancreatic Patient-derived Organoids
ConditionPancreatic Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHerlev Hospital
About this trial
EUS-FNB samples will be used for organoid cultures, which will be co-cultured with cancer associated fibroblasts derived from the surrounding stroma of the lesion. The organoid cultures will be used for pharmacotyping using relevant chemotherapeutic agents used in the clinic, and the organoid's response compared with the patient's response.
Eligibility criteria
Qualifiers
Signed informed consent
Histopathological confirmation of PDAC and planned standard first-line treatment prior to entering this study OR Patients suspected of primary locally advanced, non-metastatic PDAC based on cross-sectional imaging undergoing diagnostic standard of care (SOC) EUS-FNB procedure
Age > 18 years and older
Life expectancy greater than 3 months
Disqualifiers
Contraindications for nurse administered propofol sedation (NAPS)
Contraindications for EUS-FNB procedure
Trial design
Treatments tested in this trial
- No intervention
Treatment groups
No treatment groups listed
Sponsors and collaborators
Herlev Hospital
Lead sponsor
Rigshospitalet, Denmark
Collaborator
Source ClinicalTrials.gov